Jay M. Moyes
Mr. Moyes has served on our Board since April 2012. Since March 2020, he has
served as the Chief Financial Officer of Sera Prognostics, Inc., a private clinical-stage
biotechnology company focused on improving maternal and neonatal health through
innovative biomarker approaches, Mr. Moyes has been a member of the board of
directors of Achieve Life Sciences, Inc., a public specialty pharmaceutical company,
since August 2017 and a member of the board of directors and chairman of the audit
committee of Osiris Therapeutics, Inc., a publicly held stem cell therapeutics company,
since May 2006. He has also been a member of the board of directors and chairman of
the audit committee for Biocardia, Inc., a privately held cardiovascular regenerative
medicine company, and Integrated Diagnostics, Inc., a privately held molecular
diagnostics company, since 2011.
From May 2008 through July 2009, Mr. Moyes served as the Chief Financial Officer of
XDx, Inc., a privately held molecular diagnostics company. Prior to that, he served as
the Chief Financial Officer of Myriad Genetics, Inc., a publicly held healthcare
diagnostics company, from June 1996 until his retirement in November 2007, and as its
Vice President of Finance from July 1993 until July 2005. From 1991 to 1993, Mr.
Moyes served as Vice President of Finance and Chief Financial Officer of Genmark,
Inc., a privately held genetics company. He held various positions with the accounting
firm of KPMG LLP from 1979 through 1991, most recently as a Senior Manager. He
also served as a member of the Board of Trustees of the Utah Life Science Association
from 1999 through 2006.
Mr. Moyes holds an MBA from the University of Utah, a B.A. in economics from Weber
State University, and is formerly a Certified Public Accountant. He was selected as a
director because of his extensive background in finance and accounting in the life
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024